Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

Key facts

Study ID

NCT00588731

Run by

Yale University

People needed

41

Starts

2009-02-01

Expected to finish

2013-12-01

Last updated by the study team

2017-06-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

You may not qualify if…

• Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.

Where it is running

• Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.